Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan-Feb;21(1):11-7.
doi: 10.4103/1319-3767.151216.

Surgical treatment for hepatocellular carcinoma

Affiliations
Review

Surgical treatment for hepatocellular carcinoma

Ahmad A Madkhali et al. Saudi J Gastroenterol. 2015 Jan-Feb.

Abstract

Hepatocellular carcinoma (HCC) is an epithelial tumor derived from hepatocytes; it accounts for 80% of all primary liver cancers and ranks globally as the fourth leading cause of cancer-related deaths. HCC treatment is a multidisciplinary and a multimodal task, with surgery in the form of liver resection and liver transplantation (LT) representing the only potentially curative modality. However, there are variable opinions and discussions about applying these surgical options and using other supporting treatments. This article is a narrative review that includes articles published from 1984 to 2013 located by searching scientific databases such as PubMed, SCOPUS, and Elsevier, with the main keyword of hepatocellular carcinoma in addition to other keywords such as liver transplantation, liver resection, transarterial chemoembolization, portal vein embolization, bridging therapy, and downstaging. In this review, we focus mainly on the surgical treatment options offered for HCC, in order to illustrate the current relevant data available in the literature to help in applying these surgical options and to use other supporting treatment modalities when appropriate.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
(a) Enhanced HCC lesion in the arterial phase of a CT scan (b) Early washout of contrast in the venous phase

Similar articles

Cited by

References

    1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–43. - PubMed
    1. Kuntz E. Hepatology Textbook and Atlas: History, Part 4. Springer: Heidelberg; 2008. Malignant liver tumor; pp. 795–835.
    1. Oliver JH, 3rd, Baron RL, Federle MP, Rockette HE., Jr Detecting hepatocellular carcinoma: Value of unenhanced or arterial phase CT imaging or both used in conjunction with conventional portal venous phase contrast-enhanced CT imaging. AJR Am J Roentgenol. 1996;167:71–7. - PubMed
    1. Baron RL, Oliver JH, 3rd, Dodd GD, 3rd, Nalesnik M, Holbert BL, Carr B. Hepatocellular carcinoma: Evaluation with biphasic, contrast-enhanced, helical CT. Radiology. 1996;199:505–11. - PubMed
    1. Dodd GD, 3rd, Baron RL, Oliver JH, 3rd, Federle MP, Baumgartel PB. Enlarged abdominal lymph nodes in end-stage cirrhosis: CT-histopathologic correlation in 507 patients. Radiology. 1997;203:127–30. - PubMed